Influence of bisphosphonates in orthodontic therapy: Systematic review

Iglesias-Linares, Alejandro; Yáñez-Vico, Rosa-María; Solano-Reina, Enrique; Torrés-Lagares, Daniel; Moles, M.A. González

doi:10.1016/j.jdent.2010.05.012

Cited by 40 publications

(29 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Parmi les treize articles inclus, aucune étude n'est issue de données humaines. Les auteurs admettent que la dose reçue et la durée des BP pourraient diminuer le mouvement dentaire mais ceci n'a pas été quantifié chez l'Homme [21]. Alors que certains auteurs s'accordent à dire qu'un traitement orthodontique devrait être évité chez les adultes sous BP [22,23], Krieger et al exposent, dans une récente revue de littérature, le cas d'une adolescente de 15 ans atteinte de DF de forme polyostotique, considérée à haut risque, sous 135 mg de pamidronate IV par cure depuis deux ans, ayant bénéficié avec succès d'une greffe alvéolaire pour une fente labiopalatine avec supraclusie anté-rieure.…”

Section: Discussionunclassified

Risque d’ostéonécrose des maxillaires associé à un traitement par biphosphonates dans l’enfance

Torres

Louvet

Lacheretz

et al. 2016

Med Buccale Chir Buccale

View full text Add to dashboard Cite

Résumé -Introduction : La prise prolongée de biphosphonates (BP) par voie intraveineuse (IV) induit un risque d'ostéonécrose des mâchoires (ONM) qui augmente après la réalisation d'un geste de chirurgie orale. À ce jour, aucune ONM n'a été décrite chez des enfants ayant reçu des BP. Observation : Le cas décrit est celui d'une jeune adulte ayant reçu des BP au long cours par IV dans l'enfance pour dysplasie fibreuse (DF) et qui requiert un avis pour l'avulsion des troisièmes molaires. Discussion : La pharmacocinétique des BP à plusieurs années de distance reste difficile à évaluer faisant s'interroger sur leur sécurité d'emploi bien des années après la fin d'un traitement instauré dans l'enfance. L'enfance étant une période spécifique de turnover cellulaire élevé et de croissance, le retentissement sur l'éruption dentaire et le développement cranio-facial est à considérer lors d'une prise de BP à cette période. Conclusion : Les facteurs de risque d'ONM sur le terrain pédiatrique sont différents de ceux retrouvés chez l'adulte, ce qui, en l'absence de recommandation, pose la question de l'évaluation du risque d'ONM pour cette population particulière. Abstract -Introduction:The prolonged use of intravenous bisphosphonates (BP) leads to a risk of bisphosphonate-related osteonecrosis of the jaws (BRONJ), that increases after oral surgical procedures. To date, no cases of BRONJ have been described in children after receiving BP therapy. Observation: We describe a situation where a young female adult who had received intravenous BP therapy for prolonged periods in childhood to treat fibrous dysplasia required extraction of her third molars. Discussion: The BP pharmacokinetics after a long period of BP treatment is still difficult to assess, leading to questioning the safety of their use many years after the end of a treatment initiated in childhood. Childhood is a specific period of high cellular turnover and growth activity; therefore, the impact of such an intensive treatment on dental eruption and craniofacial skeleton growth should be taken into consideration during this time. Conclusion: BRONJ risk factors in a paediatric population are different from those of an adult population, as underlined by the lack of guidelines, and critical to assess.

show abstract

Section: Discussionunclassified

Risque d’ostéonécrose des maxillaires associé à un traitement par biphosphonates dans l’enfance

Torres

Louvet

Lacheretz

et al. 2016

Med Buccale Chir Buccale

View full text Add to dashboard Cite

show abstract

“…The methodological quality of the selected papers was assessed using a modified version (Iglesias‐Linares et al . ) of the method described by Antczak et al . () and Jadad et al .…”

Section: Reviewmentioning

confidence: 99%

Revascularization of immature permanent teeth with apical periodontitis

et al. 2013

View full text Add to dashboard Cite

The aim of this minireview was to identify and review the scientific evidence regarding regenerative endodontic protocols claiming to revascularize permanent immature teeth with apical periodontitis. The literature was identified using the PubMed/MEDLINE, Scopus, Scirus, EMBASE and Cochrane databases up to February 2013. Studies were selected independently by two different researchers (kappa index: 0.88), based on established inclusion/exclusion criteria. The methodological quality of the reviewed papers was classified as high, medium or low (HQ, MQ, LQ). The search strategy identified 285 titles. Nine studies, both human and animal based, were selected after application of the criteria (LQ:5; MQ:4). In most of these studies (seven of nine), the revascularization protocol included a triple antibiotic combination as canal disinfectant for a period of 1-4 weeks after blood clot formation (LQ:5; MQ:4), although there is no clear consensus about the treatment protocol. Two studies reported tooth discoloration after the revascularization process (LQ:2), and only three (LQ:1; MQ:2) reported a success rate of 54.9% in dogs and 73.6% and 80% in humans, respectively. Revascularization of immature permanent teeth with apical periodontitis is possible and preferable to apexification. Nevertheless, there is a widespread lack of randomized clinical trials and blinded measures. In addition, the small sample sizes that are common in these studies as well as the generally low quality of the analysed publications require the results to be viewed with caution. There is a high risk of bias, with a low quality of available information, for developing clinical guidelines for regenerative endodontic protocols; rigorous randomized clinical trials are therefore needed.

show abstract

“…Modified health status may increase the appearance risk of certain complication or interfere with the orthodontic treatment conduct. For example, in case of bisphosphonates usage, among the side effects, the orthodontist should be concerned about the difficulties of achieving a desired tooth movement (long-lasting aspect after drug discontinuation) and also about the slower bone healing rate with the possibility of osteonecrosis appearance (especially important when tooth extractions, implant placement or phases of orthognathic surgery are planned) (Iglesias-Linares et al, 2010).…”

Section: General Therapeutic Contextmentioning

confidence: 99%